DelveInsight's latest pipeline report reveals over 55 pharmaceutical companies actively developing 60+ innovative drug candidates for schizophrenia treatment, indicating significant industry investment in addressing this serious mental illness.
Spinogenix's SPG601 demonstrated a significant reduction in high-frequency gamma band activity, an EEG abnormality associated with Fragile X syndrome (FXS).
Spinogenix is developing SPG302 and SPG601, orally administered small molecules, to restore synapses in neurological diseases like ALS, Alzheimer's, schizophrenia, and Fragile X syndrome.